Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cencora, Inc.COR · Entity 2994 | Director | March 05, 2026 | March 09, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Financial Officer | May 15, 2020 | June 04, 2020 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | September 08, 2026 | September 10, 2026 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | June 13, 2019 | June 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cencora, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,081 |
Reported balance
After 2026-03-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 557 · Balance 4,081 F1: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Receipt of shares deferred until 3/10/2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Receipt of shares deferred until 3/10/2029.
Moderna, Inc.
Report date May 15, 2020 · Filed June 04, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,219,910 |
Reported balance
After 2020-05-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-05-15 · Sale · Disposed 2,600 · Balance 1,219,910 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on September 18, 2019. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.27 to $64.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on September 18, 2019.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.27 to $64.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Revolution Medicines, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectTrust | 0 |
Last balance in matching sequence
After 2026-09-08 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 2 · 2026-09-08 · Sale · Disposed 706 · Balance 16,384 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F3: The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 3 · 2026-09-08 · Sale · Disposed 999 · Balance 15,385 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F5: The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 4 · 2026-09-08 · Sale · Disposed 3,587 · Balance 11,798 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F6: The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 5 · 2026-09-08 · Sale · Disposed 2,853 · Balance 8,945 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F7: The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 6 · 2026-09-08 · Sale · Disposed 4,730 · Balance 4,215 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F8: The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 7 · 2026-09-08 · Sale · Disposed 3,844 · Balance 371 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F9: The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 8 · 2026-09-08 · Sale · Disposed 371 · Balance 0 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F10: The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. |
| Common StockSEC Table I · non-derivative | Direct | 1,191 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,191 F1: Includes 1,191 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,191 restricted stock units.
F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
F3: The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: Shares held by the Lorence Kim Revocable Trust.
F5: The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6: The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7: The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F8: The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F9: The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F10: The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Seres Therapeutics, Inc.
Report date June 13, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2029-06-12 | Direct | 15,000 |
Reported balance
After 2019-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COWEN INC.
Report date March 01, 2023 · Filed March 01, 2023
Section 16 reporting ended · disclosed 2023-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-03-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2022 (the "Merger Agreement"), by and among The Toronto-Dominion Bank, a Canadian chartered bank ("Parent"), Crimson Holdings Acquisition Co., a Delaware corporation ("Merger Sub") and an indirect wholly owned subsidiary of Parent and Cowen Inc., a Delaware corporation (the "Company"), on March 1, 2023 (the "Effective Time"), Merger Sub merged with and into the Company with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the Effective Time, each share of Class A common stock, par value $0.01 per share, of the Company ("Class A Company Common Stock") issued and outstanding immediately prior to the Effective Time and each share of Class B common stock, par value $0.01 per share, of the Company (together with Class A Company Common Stock, "Company Common Stock") issued and outstanding immediately prior to the Effective Time (except for (i) shares of Company Common Stock owned by the Company or Parent (in each case, other than shares of Company Common Stock (A) held in trust accounts, managed accounts, mutual funds and the like, or otherwise held in a fiduciary or agency capacity, or (B) held, directly or indirectly, in respect of a debt previously contracted) and (ii) any shares of Company Common Stock with respect to which dissenters' rights have been exercised) was automatically canceled and converted into the right to receive $39.00 in cash, without interest (the "Merger Consideration"). |
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-03-01 · Disposition to issuer · Disposed 8,236 · Balance 0 F3: This line item represents outstanding restricted stock units held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit held by a current or former non-employee director of the Company ("Director RSU") (whether settled or unsettled) immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the number of shares of Company Common Stock subject to such Director RSU immediately prior to the Effective Time and (ii) the Merger Consideration. F4: With respect to any Director RSUs that constitute nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the "Code") and that are not permitted to be paid at the Effective Time without triggering a Tax (as defined in the Merger Agreement) or penalty under Section 409A of the Code, the payment referenced under point 3 above shall be made at the earliest time permitted under the applicable Stock Plan (as defined in the Merger Agreement) and award agreement that will not trigger a Tax or penalty under Section 409A of the Code. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2022 (the "Merger Agreement"), by and among The Toronto-Dominion Bank, a Canadian chartered bank ("Parent"), Crimson Holdings Acquisition Co., a Delaware corporation ("Merger Sub") and an indirect wholly owned subsidiary of Parent and Cowen Inc., a Delaware corporation (the "Company"), on March 1, 2023 (the "Effective Time"), Merger Sub merged with and into the Company with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: At the Effective Time, each share of Class A common stock, par value $0.01 per share, of the Company ("Class A Company Common Stock") issued and outstanding immediately prior to the Effective Time and each share of Class B common stock, par value $0.01 per share, of the Company (together with Class A Company Common Stock, "Company Common Stock") issued and outstanding immediately prior to the Effective Time (except for (i) shares of Company Common Stock owned by the Company or Parent (in each case, other than shares of Company Common Stock (A) held in trust accounts, managed accounts, mutual funds and the like, or otherwise held in a fiduciary or agency capacity, or (B) held, directly or indirectly, in respect of a debt previously contracted) and (ii) any shares of Company Common Stock with respect to which dissenters' rights have been exercised) was automatically canceled and converted into the right to receive $39.00 in cash, without interest (the "Merger Consideration").
F3: This line item represents outstanding restricted stock units held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit held by a current or former non-employee director of the Company ("Director RSU") (whether settled or unsettled) immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the number of shares of Company Common Stock subject to such Director RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F4: With respect to any Director RSUs that constitute nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the "Code") and that are not permitted to be paid at the Effective Time without triggering a Tax (as defined in the Merger Agreement) or penalty under Section 409A of the Code, the payment referenced under point 3 above shall be made at the earliest time permitted under the applicable Stock Plan (as defined in the Merger Agreement) and award agreement that will not trigger a Tax or penalty under Section 409A of the Code.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 21:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 371 | $212.27 | $78,751.91 |
DisclosureSEC source: 0001193125-26-388156 · ownership.xml · nonDerivative · entry 8 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 0 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F10 · price: The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Shares held by the Lorence Kim Revocable Trust. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,844 | $211.36 | $812,463.23 |
DisclosureSEC source: 0001193125-26-388156 · ownership.xml · nonDerivative · entry 7 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 371 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F9 · price: The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Shares held by the Lorence Kim Revocable Trust. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,730 | $210.50 | $995,678.24 |
DisclosureSEC source: 0001193125-26-388156 · ownership.xml · nonDerivative · entry 6 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 4,215 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F8 · price: The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Shares held by the Lorence Kim Revocable Trust. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,853 | $209.56 | $597,874.68 |
DisclosureSEC source: 0001193125-26-388156 · ownership.xml · nonDerivative · entry 5 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 8,945 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F7 · price: The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Shares held by the Lorence Kim Revocable Trust. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,587 | $208.55 | $748,081.05 |
DisclosureSEC source: 0001193125-26-388156 · ownership.xml · nonDerivative · entry 4 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 11,798 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F6 · price: The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Shares held by the Lorence Kim Revocable Trust. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 999 | $207.33 | $207,124.77 |
DisclosureSEC source: 0001193125-26-388156 · ownership.xml · nonDerivative · entry 3 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 15,385 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F5 · price: The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Shares held by the Lorence Kim Revocable Trust. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 706 | $206.60 | $145,863.06 |
DisclosureSEC source: 0001193125-26-388156 · ownership.xml · nonDerivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 16,384 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F3 · price: The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · ownership.nature: Shares held by the Lorence Kim Revocable Trust. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 625 | $206.15 | $128,846.25 |
DisclosureSEC source: 0001193125-26-380277 · ownership.xml · nonDerivative · entry 8 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 17,090 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F9 · price: The transaction was executed in multiple trades at prices ranging from $206.02 to $206.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,128 | $205.19 | $436,639.85 |
DisclosureSEC source: 0001193125-26-380277 · ownership.xml · nonDerivative · entry 7 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 17,715 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F8 · price: The transaction was executed in multiple trades at prices ranging from $205.00 to $205.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 7,271 | $204.35 | $1,485,829.58 |
DisclosureSEC source: 0001193125-26-380277 · ownership.xml · nonDerivative · entry 6 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 19,843 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F7 · price: The transaction was executed in multiple trades at prices ranging from $204.00 to $204.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 26,160 | $203.55 | $5,324,823.53 |
DisclosureSEC source: 0001193125-26-380277 · ownership.xml · nonDerivative · entry 5 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 27,114 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F6 · price: The transaction was executed in multiple trades at prices ranging from $203.0055 to $203.9968, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 12,919 | $202.48 | $2,615,863.67 |
DisclosureSEC source: 0001193125-26-380277 · ownership.xml · nonDerivative · entry 4 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 53,274 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F5 · price: The transaction was executed in multiple trades at prices ranging from $202.00 to $202.9956, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 6,597 | $201.47 | $1,329,116.72 |
DisclosureSEC source: 0001193125-26-380277 · ownership.xml · nonDerivative · entry 3 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 66,193 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F4 · price: The transaction was executed in multiple trades at prices ranging from $201.00 to $201.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 300 | $200.56 | $60,168.00 |
DisclosureSEC source: 0001193125-26-380277 · ownership.xml · nonDerivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 72,790 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F3 · ownership.nature: Shares held by the Lorence Kim Revocable Trust (the "Trust"). Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:57 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 3,127 | $0.00 Strike: $162.99 | $0.00 |
DisclosureSEC source: 0001610717-26-000290 · form4.xml · derivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,127 Underlying: Common Stock · 3,127 shares Expires 2036-06-18 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:57 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000290 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,281 F1 · balance_after: Includes 1,191 restricted stock units. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:18 UTC | Cencora, Inc. COR · Entity 2994 | GrantCommon Stock | 557 | $359.28 | $200,118.96 |
DisclosureSEC source: 0001643746-26-000002 · wk-form4_1773087507.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,081 F1 · balance_after: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Receipt of shares deferred until 3/10/2029. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 11,574 | $0.00 Strike: $37.48 | $0.00 |
DisclosureSEC source: 0001610717-25-000271 · form4.xml · derivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,574 Underlying: Common Stock · 11,574 shares Expires 2035-06-26 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 3,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000271 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,090 F1 · balance_after: Includes 4,017 Restricted Stock Units. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 22:07 UTC | Cencora, Inc. COR · Entity 2994 | GrantCommon Stock | 789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140859-25-000057 · wk-form4_1741644431.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,524 F1 · price: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Receipt of shares deferred until 03/10/2028. F2 · ownership.direct: As previously disclosed in the Form 3 filed 10/7/2022 and the Form 4 filed 11/3/2022, the Reporting Person and his spouse have shared indirect beneficial ownership with respect to an additional 168 shares of COR common stock. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:21 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 16,700 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001610717-24-000359 · form4.xml · derivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,700 Underlying: Common Stock · 16,700 shares Expires 2034-06-19 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:21 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000359 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,500 F1 · balance_after: Includes 9,175 Restricted Stock Units. Read SEC document |
| June 20, 2024 Filed Jun 28, 2024 21:07 UTC Amendment | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 15,955 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001610717-24-000376 · form4.xml · derivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,955 Underlying: Common Stock · 15,955 shares Expires 2034-06-19 F2 · derivative.exercise_date: Shares subject to the Stock Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date. Read SEC document |
| June 20, 2024 Filed Jun 28, 2024 21:07 UTC Amendment | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 4,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000376 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,948 F1 · balance_after: Includes 8,623 restricted stock units ("RSUs"). Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 20:45 UTC | Cencora, Inc. COR · Entity 2994 | GrantCommon Stock | 843 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140859-24-000054 · wk-form4_1710362703.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,735 F1 · price: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Receipt of shares deferred until 03/10/2028. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:13 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 18,400 | $0.00 Strike: $24.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000130 · form4.xml · derivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2033-06-07 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 8, 2023 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:13 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000130 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,700 F1 · balance_after: Includes 13,950 Restricted Stock Units. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 20:18 UTC | Cencora, Inc. ABC · Entity 2994 | GrantCommon Stock | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140859-23-000070 · wf-form4_167873869355138.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892 F1 · shares: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant. Delivery of vested shares deferred until 3/10/2028. F1 · price: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant. Delivery of vested shares deferred until 3/10/2028. Read SEC document |
| March 01, 2023 Filed Mar 1, 2023 11:40 UTC | COWEN INC. COWN · Entity 89620 | Disposition to issuerClass A Common Stock | 8,236 | $39.00 | $321,204.00 |
DisclosureSEC source: 0001415889-23-003612 · form4-03012023_040303.xml · nonDerivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: This line item represents outstanding restricted stock units held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit held by a current or former non-employee director of the Company ("Director RSU") (whether settled or unsettled) immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the number of shares of Company Common Stock subject to such Director RSU immediately prior to the Effective Time and (ii) the Merger Consideration. F4 · price: With respect to any Director RSUs that constitute nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the "Code") and that are not permitted to be paid at the Effective Time without triggering a Tax (as defined in the Merger Agreement) or penalty under Section 409A of the Code, the payment referenced under point 3 above shall be made at the earliest time permitted under the applicable Stock Plan (as defined in the Merger Agreement) and award agreement that will not trigger a Tax or penalty under Section 409A of the Code. Read SEC document |
| March 01, 2023 Filed Mar 1, 2023 11:40 UTC | COWEN INC. COWN · Entity 89620 | Disposition to issuerClass A Common Stock | 30,000 | $39.00 | $1,170,000.00 |
DisclosureSEC source: 0001415889-23-003612 · form4-03012023_040303.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2022 (the "Merger Agreement"), by and among The Toronto-Dominion Bank, a Canadian chartered bank ("Parent"), Crimson Holdings Acquisition Co., a Delaware corporation ("Merger Sub") and an indirect wholly owned subsidiary of Parent and Cowen Inc., a Delaware corporation (the "Company"), on March 1, 2023 (the "Effective Time"), Merger Sub merged with and into the Company with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2 · price: At the Effective Time, each share of Class A common stock, par value $0.01 per share, of the Company ("Class A Company Common Stock") issued and outstanding immediately prior to the Effective Time and each share of Class B common stock, par value $0.01 per share, of the Company (together with Class A Company Common Stock, "Company Common Stock") issued and outstanding immediately prior to the Effective Time (except for (i) shares of Company Common Stock owned by the Company or Parent (in each case, other than shares of Company Common Stock (A) held in trust accounts, managed accounts, mutual funds and the like, or otherwise held in a fiduciary or agency capacity, or (B) held, directly or indirectly, in respect of a debt previously contracted) and (ii) any shares of Company Common Stock with respect to which dissenters' rights have been exercised) was automatically canceled and converted into the right to receive $39.00 in cash, without interest (the "Merger Consideration"). Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:20 UTC | Cencora, Inc. ABC · Entity 2994 | GrantCommon Stock | 558 | $0.00 | $0.00 |
DisclosureSEC source: 0001140859-22-000066 · wf-form4_166751043795860.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558 F1 · price: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Reporting Person is deferring delivery of shares until 3/10/2028. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 16:20 UTC | COWEN INC. COWN · Entity 89620 | GrantClass A Common Stock | 8,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009218 · form4-09012022_010923.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,184 F1 · price: Grant of restricted stock units for no monetary consideration. The shares underlying the restricted stock units will be delivered in accordance with the terms of the award agreement between the Issuer and the Reporting Person. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 20:58 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | PurchaseCommon Stock | 50,000 | $20.00 | $1,000,000.00 |
DisclosureSEC source: 0001567619-22-014431 · doc1.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,500 F1 · balance_after: Includes 10,500 Restricted Stock Units. Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 21:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 36,800 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001567619-22-013970 · doc1.xml · derivative · entry 2 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,800 Underlying: Common Stock · 36,800 shares Expires 2032-07-11 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of July 12, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 21:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013970 · doc1.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · balance_after: Includes 10,500 Restricted Stock Units. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 16:31 UTC | COWEN INC. COWN · Entity 89620 | PurchaseClass A Common Stock | 30,000 | $30.03 | $900,849.00 |
DisclosureSEC source: 0001179110-22-001700 · edgar.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price is the weighted average purchase price of the aggregate number of shares that were purchased by the reporting person. The shares were purchased in multiple transactions at prices ranging from $29.40 to $30.15. The reporting person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 96,660 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-018883 · form4.xml · derivative · entry 7 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,660 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,031 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-018883 · form4.xml · derivative · entry 6 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,372 Underlying: Common Stock · 66,031 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 78,309 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-018883 · form4.xml · derivative · entry 5 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,735 Underlying: Common Stock · 78,309 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · derivative.exercise_date: 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years). Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:18 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 241,000 | $58.30 | $14,050,300.00 |
DisclosureSEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 4 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,202,510 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 96,660 | $19.15 | $1,851,039.00 |
DisclosureSEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 3 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,443,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 66,031 | $19.15 | $1,264,493.65 |
DisclosureSEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 2 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,346,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 22:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 78,309 | $14.22 | $1,113,553.98 |
DisclosureSEC source: 0001127602-20-018883 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 27, 2020 Filed May 28, 2020 22:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 222,365 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-018084 · form4.xml · derivative · entry 5 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,044 Underlying: Common Stock · 222,365 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · derivative.exercise_date: 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years). Read SEC document |
| May 27, 2020 Filed May 28, 2020 22:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,635 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-018084 · form4.xml · derivative · entry 4 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,909 Underlying: Common Stock · 18,635 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 27, 2020 Filed May 28, 2020 22:07 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 241,000 | $51.13 | $12,322,330.00 |
DisclosureSEC source: 0001127602-20-018084 · form4.xml · nonDerivative · entry 3 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,202,510 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 27, 2020 Filed May 28, 2020 22:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 18,635 | $12.21 | $227,533.35 |
DisclosureSEC source: 0001127602-20-018084 · form4.xml · nonDerivative · entry 2 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,443,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 27, 2020 Filed May 28, 2020 22:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 222,365 | $14.22 | $3,162,030.30 |
DisclosureSEC source: 0001127602-20-018084 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,424,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 211,978 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-017220 · form4.xml · derivative · entry 19 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,544 Underlying: Common Stock · 211,978 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F19 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,022 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-017220 · form4.xml · derivative · entry 18 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,409 Underlying: Common Stock · 29,022 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F18 · derivative.exercise_date: 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.